Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

LuPSMA moves UpFront | first RCT data with Arun Azad and Michael Hofman

34:38
 
Share
 

Manage episode 440040001 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

195 episodes

Artwork
iconShare
 
Manage episode 440040001 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

195 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play